PPARGC1A and inflammatory bowel disease: In conclusion, Engeletin emerges as a novel multitarget therapeutic agent for IBD by restoring mitochondrial homeostasis and suppressing epithelial apoptosis via AMPK/SIRT1/PGC-1α signaling.